Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
Launched by CAIRO UNIVERSITY · Aug 8, 2025
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well two different antibiotic treatments work for serious infections caused by a tough-to-treat bacteria called Acinetobacter baumannii, which can cause severe illness in critically ill patients. The trial compares two medicines that both contain sulbactam combined with different antibiotics—ampicillin-sulbactam and cefoperazone-sulbactam—to see which one is more effective in treating these infections.
Adults aged 21 and older who show signs of sepsis (a serious response to infection) and have a confirmed infection with a specific resistant form of this bacteria may be eligible to join. People who have had allergic reactions to either of these antibiotics or who have already started similar antibiotic treatments are not eligible. Participants will receive one of the two antibiotic combinations and be closely monitored to see how well their infection responds to the treatment. This study aims to find better ways to treat these hard-to-treat infections and improve outcomes for very sick patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Inclusion criteria:
- • 1. Age ≥21 years old.
- • 2. Patient with signs and symptoms of sepsis.
- • 3. positive culture Carbapenem-resistant Acinetobacter baumannii (CRAB).
- Exclusion Criteria:
- * Exclusion criteria:
- • 1. Empirical sulbactam-based therapy against Gram-negative bacteria
- • 2. History of hypersensitivity reactions to ampicillin-sulbactam/cefoperazone-sulbactam
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Ahmed M Mukhtar, Professor Anesthesia and ICU
Study Director
Cairo Univesrsity hospitals Kasr Alainy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported